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Letter to the editor  
 
Xeroderma pigmentosum (XP) is a rare inherited disorder of DNA repair. Affected 
individuals cannot repair ultraviolet radiation (UVR)-induced DNA damage, resulting in an 
increased skin cancer risk (Bradford et al., 2011), severe sunburn in approximately 50% of 
patients, (Sethi et al., 2013) and progressive neurodegeneration in approximately 30% 
(Kraemer et al., 1987;  Totonchy et al., 2013). XP can result from defects in any of eight 
genes (XP-A to XP-G and variant), XPA-XPG being involved in nucleotide excision repair 
(NER) of DNA damage (Cleaver et al., 2009).   
 
XP-A patients, deficient in XPA protein, usually have a severe phenotype, with exaggerated 
sunburn and early onset of progressive neurodegeneration, which results in death, usually 
in the second or third decade (Anttinen et al., 2008). XPA protein is required for damage 
verification in the NER pathway. Over 20 different mutations have been identified in the 
XPA gene (States et al., 1998; Takahashi et al., 2010). Many of the reported cases come 
from Japan because of a founder mutation (c.390-1G>C) carried by 1% of the Japanese 
population (Hirai et al., 2006; Satokata et al., 1990). This results in abnormal splicing of 
mRNA and subsequent production of truncated, non-functioning XPA protein and the 
typically severe clinical phenotype.  
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Although a diagnosis of XP-A has usually been associated with poor prognosis, a number of 
XP-A patients, under long-term follow-up at the UK National XP Clinic, have a surprisingly 
mild phenotype.  To examine this finding further, a detailed genotype-phenotype study in 
this cohort was conducted. Specifically, patients were examined by specialists, and 
underwent audiometry, nerve conduction studies, brain MRI scans, and neuropsychometric 
evaluations. Informed consent was obtained from all patients and this study was performed 
in accordance with protocols approved by the Research Ethics Committee of Guy’s and St 
Thomas’ Hospitals NHS Foundation Trust, London (reference 12/LO/0325).  
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Nineteen out of 90 patients under study at the UK National XP clinic were assigned to 
complementation group A (Table 1). Twelve of these, from eight consanguineous families, 
displayed a mild XP-A phenotype with no ocular surface disease, delayed onset or lack of 
skin cancer and normal neurological and neuropsychometric evaluations (Figure 1A-H). 
Their mean age at assessment was 32 years (age range 6 to 79 years) and mean age at 
clinical diagnosis was 28 years (range 4 to 46 years), significantly higher than the more 
severely affected XP-A group with progressive neurogeneration presenting as 
developmental delay and cognitive impairment, sensorineural hearing loss, microcephaly, 
neuropathy and cerebellar signs (Table 1).  Remarkably, one of the patients, XP1CB, is aged 
79 years without any XP-related neurological problems. He spent the first thirty years of his 
life in India working largely outdoors and was only diagnosed clinically aged 46 years. These 
12 patients were all homozygous for the mutation c.555+8A>G, which has been previously 
reported by Sidwell et al., 2006 in a 61 year-old Punjabi woman with no neurological 
problems. All 12 patients included here, as well as the case described by Sidwell et al. 
originate from a 950km stretch of land around the Northern India/ Pakistan/ Afghanistan 
borders, suggesting a founder effect present in this population (Figure 1I).  
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The c.555+8A>G mutation at the eighth nucleotide of intron 4 generates a new splice donor 
site and results in aberrant splicing of intron 4 and non-functional truncated XPA protein. 
However, there is a small amount of normally spliced mRNA (Sidwell et al., 2006), which 
results in production of detectable residual normal XPA protein in immunoblots (Figure 1J). 
Comparison of the upper XPA band in lanes 9-12 with the calibration in lanes 1-6 suggests 
that 50 g extract from the mild XP-A cells has the same as or less XPA protein than 2.5 g 
normal extract (lane 2), indicating the presence of less than 5% of XPA protein in the mild 
XP-A cells. In contrast no protein is detectable in XP-A null cell line XP15BR (lanes 1 and 13). 
This residual protein carries out NER, consistent with the 5-15% of normal UDS found in 
these patients (Figure 1K). It has been shown that low levels of XPA protein, transfected into 
XPA-deficient cells, are able to significantly protect against DNA damage (Muotri et al., 
2002). This most likely explains their normal neurological phenotype.  
 
Interestingly, the sunburn reactions in this group were variable, despite all patients being of 
similar ethnicity. This may be explained by the fact that the very small amount of 
functioning XPA protein may not be sufficient to repair the high level of photoproduct 
accumulation after sun exposure, resulting in moderate sunburn severity. However 
endogenous neurological damage is likely to be generated continually, at a low rate and 
therefore the low level of functioning XPA protein may be sufficient to repair the damage as 
it forms, resulting in a normal neurological phenotype. 
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There has been a handful of other mild XP-A patients reported in the literature, although 
none as mild as our cohort. Four middle-aged Japanese XP-A patients presented with late 
onset neurological impairment and moderate sunburn reactions, without development of 
skin cancer (Takahashi et al., 2010). Their milder phenotype was attributed to frameshift 
mutations in exon 6 (c.689dupT p.(Arg231fs) in one patient, c.779delCinsTTCTT p.(Thr260fs) 
in the other three) producing truncated XPA proteins.  
 
This study highlights the importance of genotype-phenotype correlations in XP, not only for 
diagnosis but also for prognosis and genetic counselling. In this paper we present 12 XP-A 
patients with variable sunburn reactions and normal cognitive and neurological phenotype; 
the largest number of mild XP-A patients reported to date. Although the milder skin 
phenotype may be to some extent related to their more pigmented Fitzpatrick skin types, in 
our cohort of patients, homozygous for c.555+8A>G, we are now able to give cautiously 
optimistic prognostic information with regards to lack of neurodegeneration and later onset 
of skin cancer. A diagnosis of mild XP-A should be considered in individuals with facial 
lentigines, originating from the borders of Northern India, Pakistan and Afghanistan, as 
early photoprotection can reduce further development of lentigines and potential skin 
cancers. Our findings, from a relatively small immigrant population in the UK, imply that 
there may be many such individuals in the area of origin, who are likely to be undiagnosed 
because of the mildness of symptoms and may suffer from excessive skin damage later in 
life. 
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Figure legend 
Figure 1. Face views of mild xeroderma pigmentosum complementation group A (XP-A) 
patients and map of origins, immunoblots of protein extracts probed with monoclonal 
antibody to XPA protein, and measurement of UDS in mild XP-A and control cell lines. (a) 
XP103BR: Seven-year-old girl with a few facial lentigines (distantly related to patients shown 
in e-g). (b) XP53BR: Eighteen-year-old man who presented with sunburn lasting 1 week and 
increased lentigines at exposed sites. (c, d) XP2PR, XP1PR: Two siblings aged 32 and 35 
years, respectively, who developed facial lentigines at age 2 years (distantly related to 
patients shown in e-g). (e-g) XP89BR-S, XP88BR, XP89BR: Three siblings, currently aged 34, 
36, and 43 years, respectively, who presented with increased facial lentigines and easy 
sunburn. (h) XP1CB: Seventy-nine-year-old man who developed lentigines at exposed sites 
at age 6 years. Of the seven other siblings in his family, four have XP. Until 30 years of age 
he had worked outdoors as a veterinarian in India, with high cumulative ultraviolet radiation 
exposure. He then moved to the United Kingdom and worked indoors as a pathologist until 
his retirement. He developed melanoma in situ on his left cheek at age 46 years and since 
then has developed 8 melanomas and >20 nonmelanoma skin cancers. He underwent a left 
hemicolectomy for a sigmoid colon adenocarcinoma Dukes B at age 55 years, followed by 
further surgery for mucinous adenocarcinoma Dukes B2 the following year. He 
subsequently developed keratoacanthomas and a sebaceous adenoma, leading to a 
diagnosis of Muir-Torre syndrome [mutation c.306G>T in MLH-1 (Thompson et al., 2014)] 
unrelated to his mutation in the XPA gene. (i) Origins of the eight families with mild 
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XP-A are indicated on the map. (j) Immunoblots of protein extracts probed with monoclonal 
antibody to XPA protein (BD Bioscience, Oxford, UK, #556453). Left: Calibration: The 50-g 
protein extract is made up of the indicated quantities from normal 48BR cells and XPA-null 
XP15BR cells. Right: The 50 g of extract from the indicated cells. The positions of the 50-
kDa and 37-kDa markers are indicated between the panels. XPA protein, indicated with 
arrows, runs as two bands on either side of the 37-kDa marker. Normal XPA protein level of 
<5% is detected in the mild XP-A cases but not in XP15BR. (k) UDS measured by 
incorporation of 3H-thymidine into nondividing cells after ultraviolet-C irradiation with the 
indicated doses. From 5% to 15% of normal UDS is detected in cells from the mild XP-A 
patients but is undetectable in XP15BR. UDS, unscheduled DNA synthesis. All patients 
pictured here have provided written and oral consent for publication of these photographs. 
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Table 1. Summary of clinical features in XP-A patient cohort 
XP number 
Age 
(Sex) 
Country of 
Origin 
aAge at 
XP 
diagnosis 
SSS 
Cutaneous 
features 
Developmental/ 
neuropsychometric 
and neurological 
evaluation 
Age 1st 
mucocutaneous 
cancer (type) 
Mutation in XPA gene 
XP9BI 6 (F) Pakistan 6 0 Lentigines Normal  c.555+8A>G 
XP103BR 7(F) Pakistan 4 0 Lentigines Normal  c.555+8A>G 
XP53BR 18(M) Pakistan 7 1 
Lentigines / 
Photosensitivity 
Normal  c.555+8A>G 
XP121BR 25 (F) Pakistan 25 1 Lentigines Normal  c.555+8A>G 
XP116BR 31(M) India 31 1 Lentigines Normal 31 (BCC) c.555+8A>G 
XP2PR 32(F) Pakistan 32 1 Lentigines Normal  c.555+8A>G 
XP89BR-S 34(M) Pakistan 33 2 Lentigines Normal  c.555+8A>G 
XP1PR 35(M) Pakistan 35 2 Lentigines Normal  c.555+8A>G 
XP88BR 36(M) Pakistan 31 3 Lentigines Normal  c.555+8A>G 
XP49BR 38(M) Afghanistan 24 1 
Lentigines / 
Photosensitivity 
Normal  c.555+8A>G 
XP89BR 43(F) Pakistan 39 3 Photosensitivity Normal  c.555+8A>G 
XP1CA 79(M) India 67 0 Lentigines Normal 46 (MM) c.555+8A>G 
XP111BR 7(F) Bangladesh 5 3 Lentigines Abnormal  c.253C>T  p.(Gln85TER) 
XP57BR 14(F) Bangladesh 1 1 Photosensitivity Abnormal  c.640dupA  p.(Met214fs) 
XP80BR 14(F) Somalia 8 3 Photosensitivity Abnormal  c.314G>A  p.(Cys105Tyr) 
XP81BR 18(M) Somalia 12 1 Photosensitivity Abnormal  c.314G>A  p.(Cys105Tyr) 
XP15BR 22(M) UK 0.5 3 Photosensitivity Abnormal  c.266_267dupAA  p.(Val90fs) 
XP114BR 24(M) Pakistan 22 3 Photosensitivity Abnormal  22 (SCC) c.682C>T  p.(Arg228TER) 
XP20BR 32(M) Pakistan 13 3 Photosensitivity Abnormal 22 (ocular CIN3) c.682C>T  p.(Arg228TER) 
 
SSS: Sunburn severity score (Sethi et al., 2013), BCC: basal cell carcinoma, MM: malignant melanoma, SCC: squamous cell 
carcinoma, CIN: conjunctival intraepithelial neoplasia. 
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aAge of diagnosis by cellular measurement of defective NER or identification of pathogenic mutation(s). Clinical diagnosis may 
have been earlier. 
 
